---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066575"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-05-27T10:40:32+00:00"
generated_at: "2026-05-27T10:45:17.600815+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart

## Summary
- $100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.
- Up to $400M more at FDA approval ($150M at Apogee's option); total synthetic royalty up to $800M.
- Low-to-mid single digit tiered royalties for 15 years on worldwide net sales; no royalties above $8B.
- Up to $500M senior corporate debt available at mutual consent with Blackstone.
- Company removes cash runway guidance; combined with $1.3B current cash positions for self-sustainability.

## SEC filing metadata
- accession: 0001104659-26-066575
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-05-27T10:40:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/0001104659-26-066575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/tm2615568d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066575
- JSON: https://secwatch.observer/filing/0001104659-26-066575.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.